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Transplant-related mortality (TRM) after HLA-mismatched umbilical cord blood (UCB) 
transplantation is high.  In-utero exposure to the non-inherited maternal antigen (NIMA) 
is recognized by the fetus, which induces T regulator cells to that haplotype.  It is 
plausible UCB transplantations where recipients are matched to donor NIMAs may 
alleviate some of the excess mortality associated with this treatment.  To explore this 
further, we used marginal matched-pair Cox regression analysis to compare outcomes 
after 48 UCB transplantations that were NIMA-matched (i.e., the NIMA of the donor 
UCB unit was matched to the patient) to 116 transplantations that were not NIMA-
matched.  All patients had hematologic malignancies and received a single UCB unit.  
Cases and controls were matched on age, disease, disease status, transplant-conditioning 
regimen, HLA-match and infused cell dose. TRM was lower after NIMA-matched 
compared to NIMA-mismatched transplantations (relative risk=0.48, p=0.05; 18% vs. 
32% at 5 years after transplantation).  Consequently, overall survival was higher after 
NIMA-matched transplantations.  The 5-year probabilities of overall survival after 
NIMA-matched and NIMA-mismatched transplantations were 55% and 38%, 
respectively (p=0.04).  When faced with the choice of multiple HLA-mismatched UCB 
units containing adequate cell dose, selecting a NIMA-matched UCB unit may improve 



















 Umbilical cord blood (UCB) is an acceptable graft choice when considering unrelated 
donor transplantation for patients with hematologic malignancies.   In the United States, 
UCB grafts are used for about 20% of unrelated donor transplantations for hematologic 
malignancies and in Europe, for about 12%.  We and others have shown similar 
leukemia-free survival despite higher transplant-related mortality (TRM) after 
transplantation of UCB compared to transplantation of HLA-matched bone marrow or 
peripheral blood progenitor cells from unrelated adult donors in children and adults with 
leukemia.1,2   High TRM after UCB transplantation remains a significant limitation and 
can be attributed to multiple factors. Some of the excess TRM after UCB transplantation 
results from infusion of units containing a relatively low total nucleated cell (TNC) dose.   
The accepted standard now is to use a UCB unit that contains a minimum pre-
cryopreserved TNC of 3 x 107/kilogram patient body weight and others recommend an 
incremental increase in TNC to overcome the HLA-barrier.3,4  When such a unit is 
lacking, the co-infusion of two un-manipulated UCB units is used to deliver higher TNC 
doses.4,5  Infusion of expanded hematopoietic progenitor cells with a single UCB unit is 
also employed to deliver higher TNC doses.6,7 Avoiding UCB units to which donor 
specific anti-HLA antibodies are present in the recipient lowers graft failure and mortality 
risks.8-10  The importance of better donor-recipient HLA-matching for unrelated adult 
donor transplantation is clear.11 Best results are obtained with an unrelated adult donor 
allele-matched to the recipient at HLA-A, -B, -C and –DRB1.  Matching the UCB unit to 














HLA-matching at HLA-A, -B and –C remains to be determined in the setting of UCB 
transplantation. 
   Two independent clinical studies done a decade apart,13,14 observed tolerance to non-
inherited maternal antigens (NIMA) in renal transplant recipients implying that fetal 
exposure to NIMAs may promote lasting tolerance in humans.  As the fetal immune 
system develops, T cells develop tolerance to self-antigens and recognize and react 
against foreign antigens.  The placental circulation permits crossing of maternal cells to 
the fetus and vice-versa. In a recent report, Mold and colleagues showed that the human 
fetal immune system generate regulatory T cells (CD4+CD25highFoxP3+ Tregs) that 
suppress fetal immune responses to maternal antigens and that this tolerance persists at 
least until early adulthood.15   In a recent report from the New York Blood Center16  
HLA-mismatched UCB transplantations where the mismatched antigen in the recipient 
matched the NIMA of the UCB donor (NIMA-matched transplant) were associated with 
higher neutrophil recovery and lower mortality rates.  Yet, in another recent report from 
the same group,17 NIMA-matched transplants were not associated with transplant-related 
or overall mortality even though both analyses were performed on largely the same 
cohort of donor-recipient pairs.  As the majority of UCB transplants are mismatched and 
TRM a barrier to successful outcome, the current analysis was undertaken in an 
independent cohort of patients to determine whether matching the recipient to the UCB’s 
non-inherited maternal antigen (i.e., NIMA) as reported by van Rood and colleagues16 
would indeed lower some of the excess mortality associated with mismatched UCB 

















   The study includes patients reported to Eurocord-European Group for Blood and 
Marrow Transplantation and the Center for International Blood and Marrow Transplant 
Research.  To be eligible, UCB unit HLA-typing, UCB donor’s maternal HLA-typing or 
maternal sample and recipient HLA-typing had to be available. Seven Netcord Banks in 
Europe, and ten Cord Blood Banks in the National Marrow Donor Program network, in 
the U.S., provided UCB units.  Data for transplantations in Europe were obtained from 
the Eurocord and in the United States, from the Center for International Blood and 
Marrow Transplant Research.  All patients received a single unrelated umbilical cord unit 
for treatment of leukemia, lymphoma or myelodysplastic syndrome (MDS).  Patients who 
received UCB units that were matched at HLA-A, -B and –DRB1, co-infusion of two 
units or expanded units were excluded.  All patients (or their guardians) provided written 
consent for research.  The Institutional Review Boards of the Medical College of 
Wisconsin, the Eurocord-Netcord scientific committee and the National Marrow Donor 
Program approved this study. 
HLA typing and match assignment 
   Donor, donor maternal and recipient HLA-typing considered matching at HLA-A, -B 
and –DRB1.  Donor-recipient match grades were assigned considering HLA-A and -B at 
intermediate resolution (antigen level) and -DRB1 at high resolution (allele-level).  For 
transplantations facilitated by the Netcord banks, maternal HLA typings were available 
from the banks.  For transplantations facilitated by the National Marrow Donor Program, 














banked maternal samples were performed at a centralized laboratory using DNA-based 
methods.  Maternal HLA typing was scored at intermediate resolution (antigen-level) for 
HLA-A and –B and at high resolution (allele-level) for HLA-DRB1.  Assignment of 
transplantations as NIMA-matched or NIMA-mismatched, were ascertained by reviewing 
recipient, donor and donor maternal HLA typing at HLA-A, -B and –DRB1.  Transplants 
were assigned as NIMA-matched when the mismatched antigen of the recipient was 
matched to the non-inherited maternal antigen of the UCB donor (NIMA-matched 
transplant). Transplants were assigned as NIMA-mismatched when the mismatched 
antigen of the recipient was not matched to the non-inherited maternal antigen of the 
UCB donor.  Examples of NIMA-match and mismatch are shown in Table 1.   
Outcomes 
   TRM was defined as the time from transplantation to death not related to disease 
recurrence or progression and overall mortality defined as death from any cause. 
Neutrophil recovery was defined as achieving an absolute neutrophil count ≥0.5 x 109/L 
for three consecutive measurements on different days; grade 2-4 acute18 and chronic19 
graft-versus-host disease (GVHD) based on reports using standard criteria from each 
transplant center; disease recurrence based on morphological evaluation supported by 
reappearance of abnormalities in cytogenetic or molecular analyses. 
Statistical methods 
 The probabilities of TRM, recurrent disease, neutrophil recovery and acute and chronic 
GVHD were calculated using the cumulative incidence estimator to accommodate 














Meier estimator.20 95% confidence intervals (CI) were calculated with log 
transformation. 
 To assess the association between clinical outcomes and NIMA matching, cases (NIMA-
matched) were matched to controls (NIMA-mismatched).  A matched-pair analysis was 
considered appropriate given the relatively low frequency of NIMA-matched 
transplantations (8.5%).  Prior to matching cases to controls, we built multivariate Cox 
regression model for TRM using patients that met the study eligibility (n=508).21  Results 
are expressed as relative risk (RR).  The characteristics of this cohort are shown in 
Supplemental Table 1; 52 donor-recipient pairs were NIMA-matched and 456, NIMA-
mismatched.  We aimed to identify variables, other than NIMA matching, with a 
significant effect on TRM: patient age, donor-recipient HLA-match, disease status at 
transplantation and transplant conditioning regimen were significantly associated with 
TRM (Supplemental Table 2). Cases were matched to controls for patient age, HLA-
match, disease status and conditioning regimen and two other variables (disease type and 
total nucleated cell dose [TNC] ≤3 x 107/kg vs. >3 x 107/kg), known to be frequently 
associated with UCB transplantation outcomes.  
   The final study population included 48 NIMA-matched and 116 NIMA-mismatched 
transplant recipients.  Nineteen cases were matched to 76 controls (1:4), 1 case was 
matched to 3 controls (1:3), 9 cases were matched to 18 controls (1:2) and 19 cases were 
matched to 19 controls (1:1).  To assess the association between clinical outcomes and 
NIMA match status, using matched-pairs we built marginal Cox regression models for 
neutrophil recovery, acute and chronic GVHD, TRM disease recurrence and overall 














confirmed with the use of backward selection procedure. All variables met the 
proportional hazards assumption. P-values are two-sided and values of 0.05 or less were 
considered statistically significant. Analyses were performed using SAS 9.2 (SAS 
Institute, Cary, NC). 
  The frequencies of NIMA-matched and NIMA-mismatched antigens in U.S. 
transplantations were evaluated by comparing the average antigen (HLA-A, -B) and 
allele (HLA-DRB1) frequencies within the overall population. HLA frequencies for the 
U.S. donor population provided by the NMDP were used as a reference.  NIMA-matched 
and mismatched antigens/alleles were aggregated by locus and average frequency 
compared between the NIMA-matched and mismatched groups by two-sided T-test.  
Analyses were performed for the overall population and the Caucasian subset.  
RESULTS 
Patient, disease and transplant characteristics 
   Characteristics of cases and controls are shown in Table 2.  Seventy-five percent of 
patients were 16 years or younger at transplantation, 52%, male sex and 46% were CMV 
seropositive.  Acute leukemia was the most common indication for transplantation and 
74% of transplantations occurred in remission. TBI-containing myeloablative 
conditioning regimens were used for 82% of transplantations and cyclosporine alone or in 
combination with steroids, methotrexate or mycophenolate mofetil for GVHD 
prophylaxis for 86%.  Thirty-five percent of transplantations were mismatched at one and 
the remainder at two HLA-loci.  All transplantation occurred in 2002 – 2009.  Fifty 
percent of NIMA-matched and 42% of NIMA-mismatched transplants occurred between 














recipients received TNC >3 x 107/kg.  The median follow-up of surviving patients was 42 
months (range 3 – 103) after NIMA-matched and 36 months (3 – 93) after NIMA-
mismatched transplantations. 
Neutrophil recovery 
 Neutrophil recovery after NIMA-matched and NIMA-mismatched transplantations was 
not different (RR 1.18 95% CI 0.80 – 1.74, p=0.42).  The median time to recovery was 20 
and 23 days after transplantation of NIMA-matched and NIMA-mismatched units.  The 
corresponding day-28 probabilities of recovery were 71% (95% CI 57% – 81%) and 59% 
(95% CI 50% – 67%). 
Acute and chronic graft-versus-host disease 
   Risks of grade 2-4 acute GVHD (RR 0.94 95% CI 0.56 – 1.59, p=0.82) and chronic 
GVHD (RR 0.85 95% CI 0.44 – 1.63, p=0.61) were not different after NIMA-matched 
and NIMA-mismatched transplantations.  The day-100 probabilities of grade 2-4 acute 
GVHD after NIMA-matched and NIMA-mismatched transplantations were 40% (95% CI 
26% – 53%) and 46% (95% CI 37% – 54%), respectively.  The corresponding 5-year 
probabilities of chronic GVHD were 26% (95% CI 15% – 39%) and 27% (95% CI 19% – 
35%). 
Transplant-related and overall mortality  
   The risk of TRM was lower after NIMA-matched compared to NIMA-mismatched 
transplantations (RR 0.48 95% CI 0.23 – 1.01, p=0.05; Figure 1A).  Similarly, overall 
mortality risks were also lower after NIMA-matched compared to NIMA-mismatched 
transplantations (RR 0.61 95% CI 0.38 – 0.98, p=0.04; Figure 1B).  Data on infections 














(69%) transplants.  The day-30 cumulative incidence of infections was 15% and 27% 
after NIMA-matched and NIMA-mismatched transplants (p=0.24).  The corresponding 
day-100 cumulative incidence at day-100 was 48% and 50%.  Six of 20 (30%) deaths 
after NIMA-matched transplantations were attributed to TRM. Most of these deaths (4 of 
6) occurred within 6 months after transplantation (n=2 multi-organ failure, n=1 infection, 
n=1 hemorrhage).  Two deaths occurred beyond 6 months, one from infection and the 
other from chronic GVHD.  Thirty-one of 66 (47%) deaths after NIMA-mismatched 
transplantations were attributed to TRM.  Twenty-three of the 31 deaths occurred within 
6 months after transplantation (n=6 multi-organ failure, n=8 infection, n=4 adult 
respiratory distress syndrome/interstitial pneumonitis, n=2 diffuse alveolar hemorrhage, 
n=1 Epstein Barr virus post-transplant lymphoproliferative disease; cause of death was 
not reported for two patients).  Eight deaths occurred beyond 6 months (n=2 chronic 
GVHD, n=3 infection, n=2 multi-organ failure; cause of death was not reported for 1 
patient). 
Relapse 
   Relapse risks after NIMA-matched and NIMA-mismatched transplants were not 
different (RR 0.82 95% CI 0.47 – 1.43, p=0.47).  The 5-year probabilities of relapse were 
31% (95% CI 18% – 44%) after NIMA-matched transplantations and 33% (95% CI 24% 
– 42%) after NIMA-mismatched transplantations.  
The influence of antigen frequency on NIMA matching  
   The frequencies of NIMA-matched and NIMA-mismatched antigens/alleles were 
evaluated for the U.S cohort (N=429).  Transplantations in Europe were excluded 














antigen (HLA-A, B) and allele (HLA-DRB1) frequencies observed on the NMDP’s donor 
registry served as the reference for the population and were adjusted based on subject 
race.  Overall, NIMA-matched antigens/alleles had higher population based frequencies 
than NIMA-mismatched antigens/alleles (NIMA-matched 0.110 vs. NIMA-mismatched 
0.052, p<0.001).  The NIMA matches were all associated with relatively common HLA 
antigens (frequencies >0.058) while the NIMA mismatched antigens were observed 
across common and uncommon HLA antigens.  The most frequent NIMA-match (N=6, 
22%) was at HLA-A*02, which is also the most common antigen in the U.S. Caucasian 
population (frequency = 0.308).22 To ensure that HLA-A*02 was not inordinately 
influencing these results, we repeated the analysis restricting the population to non-HLA-
A*02 mismatches.  Consistent with the main analysis, non-HLA-A*02 NIMA-matched 
antigens had higher frequencies compared to NIMA-mismatched antigens (NIMA-
matched 0.107 vs. NIMA-mismatched 0.054, p=0.008).   
DISCUSSION 
  Our primary objective was to assess the effect of tolerance to NIMA and its effect on 
mortality after HLA-mismatched UCB transplantation. Tolerance to NIMA in renal 
transplantation is well documented.13,14  In contrast, tolerance to NIMA and its effect on 
survival after mismatched UCB transplant is by no means conclusive.16,17 To circumvent 
the relatively small sample of NIMA-matched transplantations we adopted a matched-
pair analysis, matching recipients for factors that influence TRM and overall survival, 
which allowed us to perform a carefully controlled analysis.  We observed marginally 
lower TRM and overall mortality after NIMA-matched compared to NIMA-mismatched 














UCB transplantation.16 We hypothesize, allowing for permissive mismatching between 
UCB unit and the recipient lowered some of the excess mortality associated with HLA-
mismatched UCB transplantation. But the exact mechanism by which mortality is 
reduced is not easily explained.  Higher survival after NIMA-matched transplants is 
likely to have been mediated by multiple factors such as better hematopoietic recovery, 
lower acute GVHD, lower rate of infections in the early post-transplant period and better 
immune reconstitution which together contributed to the observed survival advantage.  
  Unlike reports after haplo-identical transplantations,23 we failed to see significant 
differences in acute or chronic GVHD rates after NIMA-matched and NIMA-mismatched 
UCB transplantations.  Acute and chronic GVHD rates after UCB transplants are 
substantially lower than after haplo-identical transplants; as only about 10% of 
mismatched UCB transplants are NIMA-matched, several hundreds of patients are 
needed before we can conclude whether there are differences in GVHD rates after 
NIMA-matched and NIMA–mismatched transplantations.   
   Better HLA-matching of donors and recipients is associated with better hematopoietic 
recovery and consequently lower early mortality.  In the current analysis, there is a 12% 
difference in the probability of neutrophil recovery after NIMA-matched and NIMA-
mismatched transplants.  Our inability to detect a statistically significant difference can 
be explained by the small sample size and the ensuing wide confidence intervals of 
probability estimates.  Further, the use of UCB units with relatively high TNC (>3 x 
107/kg) may have also lessened the importance of NIMA-matching for neutrophil 
recovery as has been shown to be the case with HLA-mismatched UCB transplants.3,24 














transplantations where very high cell doses are used have also failed to show an 
association between NIMA-matching and neutrophil recovery.23,25   It is noteworthy that 
most deaths from transplant-related complications occurred within six months from 
transplantation.  There may be differences in immune reconstitution after NIMA-matched 
and NIMA-mismatched transplants, a hypothesis we cannot test in this population.  We 
used data reported to transplant registries and data on immune reconstitution are not 
available.  
   NIMA-matched transplants account for less than 10% of UCB transplants.  
Incorporating NIMA-matching in an algorithm for UCB unit selection is complex and 
logistically challenging. As maternal HLA-typing is not listed for banked UCB units, 
NIMA-matched transplants are more likely to occur randomly than by choice.  However, 
about a third of the cord banks in Netcord / National Marrow Donor Program routinely 
perform UCB unit maternal HLA typing and listing maternal and UCB unit HLA typing 
will allow physicians select UCB units that are NIMA-matched to the recipient.  Further, 
based on our observations of the HLA types within the U.S. study cohort, NIMA-
matching correlated with the frequency of mismatched antigens within the U.S. 
population. Therefore, searching for a NIMA-matched UCB unit would best be facilitated 
by selecting a mismatched UCB unit where the mismatch is a high frequency HLA-
antigen within the target population, such as HLA A*02 in Caucasians.21   However, to 
truly understand the probability of finding a NIMA-match within a given population will 
require either complex mathematical models based on HLA haplotype frequencies or the 
addition of maternal HLA typing to UCB unit registries.  Consultation with an HLA 














identify a potential NIMA-matched UCB unit and request donor maternal HLA typing at 
time of confirmatory HLA typing of the UCB unit.  The additional request for maternal 
HLA typing to those banks that do not routinely perform maternal HLA typing will add 
to their financial burden.   
   Taken together, the current analysis and the earlier report16 suggest selecting units 
where the recipient is matched to the donor NIMA may ameliorate some of the excess 
mortality associated with HLA-mismatched UCB transplantations.  But both reports are 
limited by modest numbers of NIMA-matched transplants. Although we performed a 
carefully controlled analysis that considered risk factors associated with higher mortality 
risks, there are several unknown and unmeasured factors that may have also influenced 
survival after UCB transplantation.  Nevertheless, the marginal survival advantage 
associated with NIMA-matched transplants cannot be ignored. Therefore, when 
considering mismatched UCB transplant for hematologic malignancy, efforts to obtain 
donor maternal HLA typing from cord blood banks are encouraged.  Matching recipients 
to donor non-inherited maternal antigen must be considered along with other known 
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Table 1.  Examples of NIMA matching (A) and NIMA mismatching (B) in the setting of 
a single locus mismatched umbilical cord blood transplants. 
 
A. NIMA matched: HLA-A *24 is not carried by UCB donor.  HLA-A *24 is carried 
by the UCB donor’s mother and the recipient.  Therefore this is a NIMA-matched 
transplant. 
 
 HLA-A HLA-B HLA-DRB1 
UCB unit / donor A*02, 32 B*18, 35 DRB1*01:01, 11:04 
UCB donor mother A*24, 32 B*07, 35 DRB1*01:01, 13:01 
Recipient A*02, 24 B*18, 35 DRB1*01:01, 11:04 
 
 
B. NIMA mismatched: HLA-A *01 is not carried by UCB donor or the UCB donor’s 
mother.  Therefore this is a NIMA-mismatched transplant. 
 
 HLA-A HLA-B HLA-DRB1 
UCB unit / donor A*02, 32 B*18, 35 DRB1*01:01, 11:04 
UCB donor mother A*24, 32 B*07, 35 DRB1*01:01, 13:01 





















Number 116 48 
Region    
   Europe 37 (32%) 27 (56%) 
   United States 79 (68%) 21 (44%) 
Age   
   ≤16 years 91 (78%) 30 (62%) 
  >16 years 25 (22%) 18 (38%) 
Disease    
   Acute myeloid leukemia 48 (41%) 21 (44%) 
   Acute lymphoblastic leukemia 47 (41%) 18 (38%) 
   Chronic myeloid leukemia 1 (1%) 1 (2%) 
   Myelodysplastic syndrome 10 (9%) 4 (8%) 
   Other acute leukemia 8 (7%) 3 (6%) 
   Non-Hodgkin lymphoma 2 (2%) 1 (2%) 
Disease status   
  1st complete remission/chronic phase 31 (27%) 12 (25%) 
  2nd complete remission/chronic 
phase/accelerated phase 
56 (48%) 22 (46%) 
   Relapse, refractory anemia with excess blasts 29 (25%) 14 (29%) 
Conditioning regimen   
Myeloablative    
  Total body irradiation containing 58 (50%) 19 (40%) 
   Non-irradiation containing 43 (37%) 15 (31%) 
Reduced intensity    
  Total body irradiation containing 13 (11%) 10 (20%) 
   Non-irradiation containing 2 (1%) 4 (8%) 
Infused total nucleated cell dose   
   ≤3 x 107/kg recipient body weight 25 (22%) 16 (33%) 
   >3 x 107/kg recipient body weight 91 (78%) 32 (67%) 
GVHD prophylaxis   
   Cyclosporine alone or with steroids 56 (48%) 23 (48%) 
   Cyclosporine + methotrexate 12 (10%) 5 (10%) 
   Cyclosporine + mycophenolate mofetil 31 (27%) 14 (29%) 
   Tacrolimus + methotrexate 7 (6%) 3 (6%) 
   Tacrolimus + mycophenolate mofetil 5 (4%) 1 (2%) 
   Tacrolimus alone 5 (4%) 2 (4%) 
Donor-recipient HLA match   
   5/6 HLA match 43 (36%) 14 (27%) 

















Figure 1A: The 5-year probabilities of transplant-related mortality are 18% (95% CI 8% 
– 29%) after NIMA-matched and 32% (95% CI 23% – 41%) after NIMA-mismatched 
transplantations.   
Figure 1B: The 5-year probabilities of overall survival are 55% (95% CI 40% – 69%) 
after NIMA-matched and 38% (95% CI 29% – 48%) after NIMA-mismatched 
transplantations. 
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